What is the latest LINCOLN stock price?
The latest stored price for LINCOLN is Rs 504.35 as of 2026-11-03.
gimli
LINCOLN stock AI analysis
LINCOLN Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
LINCOLN PHARMA LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available LINCOLN price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹504.35
1W return
-8.31%
1M return
-13.35%
3M return
-13.16%
6M return
-21.90%
1Y return
-5.45%
Market cap
₹1,010.20 cr
PE
10.47
PB
1.33
ROE
+13.49%
ROCE
+16.91%
RSI
36.67
Turnover
₹1.06 cr
Why it can matter in screens
- Momentum: LINCOLN is below 50DMA, below 200DMA; RSI is 36.67.
- Returns: 1D -1.53%, 1W -8.31%, 1M -13.35%, 3M -13.16%, 1Y -5.45%.
- Trend levels: 52W high ₹659.45, 52W low ₹494.10, off high -23.52%.
- Liquidity: latest turnover is ₹1.06 cr; volume vs 20D is +0.37%.
- Valuation/profitability: PE 10.47, PB 1.33, ROE +13.49%, ROCE +16.91%.
- Growth: 3Y sales CAGR +9.94%, 3Y profit CAGR +6.43%.
Quick Answers
Is LINCOLN above its 50DMA and 200DMA?
LINCOLN is below 50DMA, below 200DMA. The latest 50DMA is 579.01 and the latest 200DMA is 593.57.
What are LINCOLN PE, ROE and ROCE?
LINCOLN has PE 10.47, ROE +13.49%, and ROCE +16.91% in Gimli's latest available snapshot.
How has LINCOLN performed recently?
LINCOLN has returned -13.35% over 1 month, -13.16% over 3 months, and -5.45% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 177.28 cr | 51.70 cr | 36.23 cr | 18.09 |
| 2026-03-31 | 187.28 cr | 20.66 cr | 11.63 cr | 5.81 |
| 2025-12-31 | 166.32 cr | 38.74 cr | 28.60 cr | 14.28 |
| 2025-09-30 | 163.36 cr | 32.66 cr | 19.98 cr | 9.98 |
| 2025-06-30 | 154.07 cr | 39.08 cr | 27.68 cr | 13.82 |
| 2025-03-31 | 168.18 cr | 19.84 cr | 11.57 cr | 5.78 |
| 2024-12-31 | 146.55 cr | 32.63 cr | 20.77 cr | 10.37 |
| 2024-09-30 | 161.21 cr | 38.36 cr | n/a | 13.15 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 671.03 cr | 131.14 cr | 87.89 cr | 43.88 |
| 2025-03-31 | 623.23 cr | 123.97 cr | 82.35 cr | 41.11 |
| 2024-03-31 | 580.55 cr | 133.81 cr | 93.30 cr | 46.58 |
| 2023-03-31 | 504.95 cr | 111.28 cr | 72.90 cr | 36.40 |
| 2022-03-31 | 482.08 cr | 104.95 cr | 69.35 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 890.40 cr | 21.53 cr | 4.42 cr | 757.63 cr |
| 2025-03-31 | 797.01 cr | 13.41 cr | n/a | 671.67 cr |
| 2024-03-31 | 700.29 cr | 5.75 cr | 1.07 cr | 592.84 cr |
| 2023-03-31 | 587.42 cr | 5.05 cr | 2.00 cr | 502.47 cr |
| 2022-03-31 | 534.36 cr | 6.93 cr | 2.04 cr | 432.88 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 106.36 cr | 80.32 cr | n/a |
| 2025-03-31 | 93.02 cr | 73.77 cr | n/a |
| 2024-03-31 | 63.22 cr | 23.60 cr | n/a |
| 2023-03-31 | 39.26 cr | 24.98 cr | n/a |
| 2022-03-31 | 76.13 cr | 30.61 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +49.78% | +4.60% | +0.27% | +0.00% | +45.36% | +0.00% |
| 2026-03-31 | +49.78% | +5.19% | +1.09% | +0.00% | +43.94% | +0.00% |
| 2025-12-31 | +49.78% | +4.70% | +0.01% | +0.00% | +45.52% | +0.00% |
| 2025-09-30 | +49.78% | +4.72% | +0.01% | +0.00% | +45.49% | +0.00% |
| 2025-06-30 | +49.78% | +5.14% | +0.01% | +0.00% | +45.07% | +0.00% |
| 2025-03-31 | +49.78% | +5.00% | +0.01% | +0.00% | +45.22% | +0.00% |
| 2024-12-31 | +49.78% | +5.16% | +0.00% | +0.00% | +45.06% | +0.00% |
| 2024-09-30 | +49.78% | +5.19% | +0.00% | +0.00% | +45.03% | +0.00% |
| 2024-06-30 | +49.78% | +3.95% | +0.04% | +0.00% | +46.24% | +0.00% |
| 2024-03-31 | +49.53% | +3.93% | +0.05% | +0.00% | +46.49% | +0.00% |
| 2023-12-31 | +49.80% | +3.23% | +0.06% | +0.00% | +46.91% | +0.00% |
| 2023-09-30 | +49.80% | +2.59% | +0.00% | +0.00% | +47.60% | n/a |
| 2023-06-30 | +47.95% | +1.74% | +0.00% | +0.00% | +50.30% | n/a |
| 2023-03-31 | +46.28% | +1.27% | +0.00% | +0.00% | +52.46% | +0.00% |
| 2022-12-31 | +45.61% | +1.44% | +0.00% | +0.00% | +52.94% | +0.00% |
| 2022-09-30 | +43.36% | +0.63% | +0.00% | +0.00% | +56.01% | +0.00% |
| 2022-06-30 | +43.36% | +0.00% | +0.64% | n/a | n/a | n/a |
| 2022-03-31 | +41.32% | +0.00% | +0.77% | n/a | n/a | +0.00% |
| 2021-12-31 | +41.28% | +0.00% | +0.95% | n/a | n/a | n/a |
| 2021-09-30 | +39.55% | +0.00% | +0.75% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze LINCOLN PHARMA with valuation, momentum and industry peers
- Compare LINCOLN with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare LINCOLN with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.